MENU
+Compare
PALI
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$0.70
Change
-$0.01 (-1.41%)
Capitalization
3.5M

PALI Palisade Bio Forecast, Technical & Fundamental Analysis

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier... Show more

PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PALI with price predictions
Jun 27, 2025

Momentum Indicator for PALI turns positive, indicating new upward trend

PALI saw its Momentum Indicator move above the 0 level on June 23, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for PALI just turned positive on June 24, 2025. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

PALI moved below its 50-day moving average on June 26, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PALI crossed bearishly below the 50-day moving average on June 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PALI entered a downward trend on June 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.656) is normal, around the industry mean (16.366). P/E Ratio (0.018) is within average values for comparable stocks, (58.189). PALI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (11.779) is also within normal values, averaging (252.247).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7750 El Camino Real
Phone
+1 858 704-4900
Employees
9
Web
https://www.palisadebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LGHL2.980.34
+12.88%
Lion Group Holding Ltd
PAYC227.231.77
+0.79%
Paycom Software
VCEL41.730.07
+0.17%
Vericel Corp
SEPN10.51-0.36
-3.31%
Septerna Inc
LEE6.28-0.38
-5.78%
Lee Enterprises

PALI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with CDTX. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
-1.93%
CDTX - PALI
82%
Closely correlated
+0.24%
WINT - PALI
81%
Closely correlated
+21.49%
SNPX - PALI
81%
Closely correlated
+23.37%
NCNA - PALI
81%
Closely correlated
N/A
NBY - PALI
80%
Closely correlated
+0.97%
More

Groups containing PALI

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
-1.93%
PALI
(21 stocks)
6%
Poorly correlated
+0.39%